Library
Commentary on "Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies" by Sievers et al.
1 July 2021. doid: 10.1111/bcp.14823
Rissmann R, Zuiker R
View publicationAdvancing the boundaries of clinical drug development
Wondering how we can help you? Reach out to us.
